Last reviewed · How we verify
NCT04194216
Antibiotic Prophylaxis in Rhinoplasty
Phase 3 trial testing Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg. in Nasal Obstruction in 864 participants. Enrolling by invitation.
20 December 2026
Quick facts
| Lead sponsor | Stanford University |
|---|---|
| Phase | Phase 3 |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 864 |
| Start date | 20 May 2020 |
| Primary completion | 20 December 2026 |
| Estimated completion | 20 April 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg. — full drug profile →
- Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days
Conditions studied
- Nasal Obstruction — all drugs for Nasal Obstruction →
- Nasal Surgical Procedures — all drugs for Nasal Surgical Procedures →
Sponsor
Stanford University
Who can join
18 and older, any sex, with Nasal Obstruction or Nasal Surgical Procedures. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study compares the efficacy of a single intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides), alone versus both intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides) and postoperative oral dose of "cephalexin" or "clindamycin" use in nasal surgery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04194216
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Nasal Obstruction
Currently open trials in the same condition.
- NCT06580210 — Performance and Safety Assessment of the Mechanical Decongestant Seawater Spray Enriched With Essential Oils From Labora · recruiting
- NCT06830109 — Nasal Obstruction With Oxymetazoline and Corticosteroids · Phase 2 · recruiting
- NCT06670261 — Diagnosis of Respiratory Disorders by the Numerical Modeling. · recruiting
- NCT05494346 — Safety and Performance Assessment of the Decongestant Seawater Spray Pocket Valve Enriched With Essential Oils in Patien · NA · recruiting
- NCT05920330 — Nasal Obstruction and Olfactory Losses · NA · recruiting
Other Stanford University trials
Trials by the same sponsor.
- NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
- NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
- NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
- NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
- NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04194216 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stanford University
- Last refreshed: 24 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04194216.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing